| __timestamp | Regeneron Pharmaceuticals, Inc. | Sarepta Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 205018000 | 94103000 |
| Thursday, January 1, 2015 | 392709000 | 146194000 |
| Friday, January 1, 2016 | 299694000 | 130000 |
| Sunday, January 1, 2017 | 397061000 | 7353000 |
| Monday, January 1, 2018 | 434100000 | 34193000 |
| Tuesday, January 1, 2019 | 782200000 | 56586000 |
| Wednesday, January 1, 2020 | 1119900000 | 63382000 |
| Friday, January 1, 2021 | 2437500000 | 97049000 |
| Saturday, January 1, 2022 | 1560400000 | 139989000 |
| Sunday, January 1, 2023 | 1815800000 | 150343000 |
| Monday, January 1, 2024 | 1970500000 |
Unleashing insights
In the competitive landscape of biotechnology, cost efficiency is a critical factor for success. This analysis delves into the cost of revenue trends for Regeneron Pharmaceuticals, Inc. and Sarepta Therapeutics, Inc. from 2014 to 2023. Regeneron, a leader in the field, has consistently managed its cost of revenue, peaking at approximately $2.44 billion in 2021. This represents a staggering 1,100% increase from 2014. In contrast, Sarepta's cost of revenue, while significantly lower, has shown a steady rise, reaching around $150 million in 2023, marking a 60% increase over the same period. The data highlights Regeneron's robust growth and operational efficiency, while Sarepta's gradual increase suggests a strategic scaling of operations. This comparison underscores the diverse strategies employed by biotech firms in managing costs while driving innovation.
Cost of Revenue Trends: Johnson & Johnson vs Sarepta Therapeutics, Inc.
Regeneron Pharmaceuticals, Inc. vs Insmed Incorporated: Efficiency in Cost of Revenue Explored
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and HUTCHMED (China) Limited's Expenses
Cost of Revenue Comparison: Regeneron Pharmaceuticals, Inc. vs Agios Pharmaceuticals, Inc.
Cost Insights: Breaking Down Regeneron Pharmaceuticals, Inc. and Amphastar Pharmaceuticals, Inc.'s Expenses
Regeneron Pharmaceuticals, Inc. vs Celldex Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
United Therapeutics Corporation vs Sarepta Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Insmed Incorporated vs Sarepta Therapeutics, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue Comparison: Sarepta Therapeutics, Inc. vs Pharming Group N.V.
Analyzing Cost of Revenue: Sarepta Therapeutics, Inc. and Geron Corporation
Analyzing Cost of Revenue: Sarepta Therapeutics, Inc. and Viridian Therapeutics, Inc.